Latest news on Alzheimer's

Under the motto "We make science happen", the Barcelona Biomedical Research Park's open day seeks to make the activity of the centers that make up the Park known on the street.

The second call for applications for the Pasqual Maragall Researchers Programme (PMRP) will distribute a total of 1.6 million euros between the two selected projects.

Ms. Glòria Oliver has been appointed Deputy General Director and Dr. Josep Maria Argimon has been appointed the new Director of Relations with the Healthcare System to strengthen this key axis.

This September 21st, with the initiative "Alzheimer's research has a name and surname", we highlight those people who work daily to bring us closer to our goal of a world without Alzheimer's: our research team

This is the first drug approved by the US regulatory agency through the traditional route that intervenes in the progression of the disease.

The work focuses on the role of pathophysiological processes beyond amyloidosis and tauopathy, and modifiable risk factors in the early development of Alzheimer’s disease during its preclinical stage.

During the meeting, the teams will disseminate the news of their research in the international scientific community.

This is one of the main conclusions of a study led by BBRC and published in Alzheimer’s and Dementia.

The research, based on data from 320 participants of the Alfa cohort, promoted by the ”la Caixa” Foundation, concludes that nutritional interventions could prevent the disease.